Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies

Inclusion Criteria: 1. Age: 18-65 years 2. Patients with Cluster of Differentiation 22(CD22) positive B cell malignancies as confirmed by flow cytometry 3. Refractory or relapsed B cell-acute lymphoblastic leukemia 4. No available curative treatment options (such as hematopoietic stem cell transplantation) 5. Stage III-IV disease 6. Creatinine \< 2.5 mg/dl 7. Aspartate transaminase-alanine transaminase ratio \< 3x normal 8. Bilirubin \< 2.0 mg/dl 9. Karnofsky performance status \>= 60 10. Expected survival time \> 3 months 11. Adequate venous access for apheresis 12. Ability to understand and provide informed consent Exclusion Criteria: 1. Pregnant or lactating women 2. Patients requiring T cell immunosuppressive therapy 3. Active central nervous system leukemia 4. Any concurrent active malignancies 5. Patients with a history of a seizure disorder or cardiac disorder 6. Previous treatment with any immunotherapy products 7. Patients with human immunodeficiency virus, hepatitis B or C infection 8. Uncontrolled active infection